| Sep 9 |
Ionis announces proposed public offering of common stock
|
| Sep 5 |
Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?
|
| Sep 4 |
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
|
| Sep 4 |
Biogen announces trial win for higher Spinraza doze
|
| Sep 4 |
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
|
| Sep 4 |
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
|
| Aug 28 |
Ionis to present at upcoming investor conferences
|
| Aug 15 |
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
|
| Aug 11 |
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
|
| Aug 7 |
Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary
|
